On 10 January, Illumina of San Diego, California, announced that it has formed a venture that will use genetic-sequencing technology to detect cancer through a simple blood test. Such a ‘liquid biopsy’ would identify tumour-specific DNA or RNA in the blood before a person has begun to show symptoms. The Illumina announcement made a splash because of its backing — US$100 million in funding, with investors including Bill Gate...
Panasonic PhotoMOS® Photovoltaic MOSFET High-Power Drivers
Adam-Tech Wire-to-Board Solutions